For Doctors in a Hurry
- Researchers investigated whether hospitals earn higher markup margins on oncology biosimilars and if these financial incentives accelerate clinical adoption.
- This observational study analyzed insurance and pricing data from 2020 to 2024, including 66,139 patients treated across 1541 hospitals.
- Slower reimbursement declines increased hospital markups, driving bevacizumab biosimilar adoption from 32 percent to 93 percent by 2024.
- The authors concluded that expanding hospital profit margins from administering oncology biosimilars directly accompanied large increases in their clinical utilization.
- Aligning payment methods between insurers and hospitals remains critical to share savings and sustain the adoption of less costly biologic alternatives.
The Economic Engine Behind Biosimilar Adoption
The expiration of patents for widely used oncology biologics has ushered in a wave of biosimilar alternatives, prompting a shift in how clinicians manage cancer treatments. Meta-analyses encompassing 31 randomized controlled trials and 12,310 patients have consistently demonstrated that biosimilars for monoclonal antibodies like trastuzumab, bevacizumab, and rituximab offer efficacy and safety profiles that are statistically indistinguishable from their reference products [1, 2]. Specifically, in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, trastuzumab biosimilars show no significant difference in objective response rates (relative risk 1.05, 95% confidence interval 0.98 to 1.12) or serious treatment-emergent adverse effects (relative risk 0.97, 95% confidence interval 0.76 to 1.25) [3]. Because these agents provide comparable clinical benefits while reducing acquisition costs to 69% to 90% of the reference price, pharmacoeconomic evaluations globally support their use to improve healthcare affordability [4, 5]. However, the actual rate at which healthcare systems integrate these therapies depends heavily on underlying financial incentives, and a recent study offers fresh insights into how the gap between hospital purchasing costs and insurance reimbursement rates is driving the rapid clinical uptake of these medications.
Tracking the Cost Gap in Oncology Care
As physician-administered oncology biologics lose patent protection, they face increasing competition from biosimilars. Because these medications represent a substantial portion of cancer care costs, hospitals and insurers share a mutual interest in developing payment methods that capture the potential savings from adopting these less costly agents. To understand how these financial incentives operate in clinical practice, researchers conducted an observational study using 2020 to 2024 data for patients covered by Blue Cross Blue Shield health insurance. The analysis included a large cohort of 66,139 patients who received oncology biologics and biosimilars across 1541 hospitals.
The researchers evaluated the spread between the acquisition prices hospitals paid to manufacturers and the higher reimbursement prices paid by private insurers. To capture the full economic picture, the investigators linked insurance claims to drug pricing data, alongside hospital eligibility for federal 340B price discounts (a government program requiring pharmaceutical manufacturers to sell outpatient drugs at discounted prices to healthcare organizations caring for uninsured and low-income patients). The primary measures for the analysis included acquisition prices, reimbursement rates, hospital drug price markup margins, and the subsequent hospital adoption of biosimilars. By tracking these metrics, the study tested whether hospitals earned higher markup margins for physician-administered oncology biosimilars and whether insurers shared in the savings by reducing reimbursement rates. Ultimately, the researchers sought to determine if increased hospital margins were associated with accelerated adoption of biosimilars, providing insight into how institutional financial health directly influences the availability of specific therapies on hospital formularies and, consequently, daily clinical prescribing patterns.
Acquisition Costs Plummet While Reimbursements Lag
Between 2020 and 2024, the financial landscape for oncology biosimilars shifted dramatically as the cost for hospitals to purchase these drugs fell sharply. Acquisition prices paid by hospitals to drug manufacturers declined by 60% for the biosimilars of bevacizumab, 72% for the biosimilars of trastuzumab, and 63% for the biosimilars of rituximab. However, the financial compensation hospitals received for administering these medications did not fall at the same rate. The reimbursement prices paid by insurers to hospitals declined more slowly, dropping by 32% for bevacizumab biosimilars, 36% for trastuzumab biosimilars, and 34% for rituximab biosimilars. Because the drop in insurance payouts lagged behind the steep discounts in purchasing costs, hospitals experienced a significant increase in their markup margins.
To quantify the relationship between purchasing costs and insurance payouts, the researchers conducted multivariable regression analyses (a statistical technique that isolates the effect of specific financial variables while controlling for confounding factors like hospital characteristics). The data demonstrated that higher purchasing costs consistently translated into disproportionately higher insurance payouts. Specifically, each additional dollar of acquisition price was associated with $2.72 in higher hospital reimbursement for bevacizumab (95% CI, $0.51 to $4.93). Similar financial dynamics were observed for the other studied agents, with each additional dollar of acquisition price associated with $1.82 in higher hospital reimbursement for trastuzumab (95% CI, $1.27 to $2.38) and $2.32 in higher hospital reimbursement for rituximab (95% CI, $1.56 to $3.09). For practicing oncologists, these figures illustrate how the current reimbursement structure financially incentivizes hospital systems to stock and promote biosimilars, expanding the margin between the cost of the drug and the revenue generated from its administration.
Financial Incentives Drive Rapid Clinical Uptake
The financial dynamics of drug procurement directly influenced clinical prescribing patterns during the study period. The researchers found that increases in hospital markup margins were strongly associated with the increased adoption of biosimilars. As the gap between acquisition costs and insurance reimbursements widened, hospitals rapidly transitioned their formularies to favor these lower-cost alternatives. This shift resulted in a dramatic surge in utilization across multiple common oncology agents. For example, the share of bevacizumab biosimilar use rose from 32% in 2020 to 93% by 2024. Similar trajectories occurred with other targeted therapies, as the share of trastuzumab biosimilar use rose from 37% in 2020 to 87% by 2024, and the share of rituximab biosimilar use rose from 18% in 2020 to 84% by 2024.
For practicing oncologists, these data highlight the powerful role of institutional economic incentives in driving systemic changes in cancer care delivery. The findings demonstrate that hospital price markup margins from the administration of oncology biosimilars have increased over time and have been accompanied by large increases in the utilization of these therapies. By aligning the financial interests of healthcare facilities with the adoption of less expensive biologic alternatives, the current reimbursement landscape has effectively accelerated the integration of biosimilars into routine clinical practice, ensuring that cost-effective therapies reach patients more rapidly.
References
1. Yang J, Yu S, Yang Z, et al. Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2019. doi:10.1007/s40259-019-00358-1
2. Bloomfield D, D'Andrea E, Nagar S, Kesselheim A. Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis.. JAMA oncology. 2022. doi:10.1001/jamaoncol.2021.7230
3. Cargnin S, Shin JI, Genazzani AA, Nottegar A, Terrazzino S. Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials.. Cancer chemotherapy and pharmacology. 2020. doi:10.1007/s00280-020-04156-3
4. Luo X, Du X, Li Z, et al. Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China: A Systematic Review and Meta-Analysis.. JAMA network open. 2023. doi:10.1001/jamanetworkopen.2023.37348
5. Huang H, Liu C, Yu Y, et al. Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review.. Frontiers in pharmacology. 2020. doi:10.3389/fphar.2020.572569
